Contact
searchSearch
HMP Global

Health Care Economics

Managed Care Q&A
2025 Drugs to Watch: Market Access, Innovation, and the Future of Reimbursement
02/28/2025
In this interview, guest experts John Stahl and Roy Moore explore the evolving payer landscape in 2025, discussing the growing role of value-based agreements, real-world evidence, and innovative reimbursement models in supporting the adoption...
In this interview, guest experts John Stahl and Roy Moore explore the evolving payer landscape in 2025, discussing the growing role of value-based agreements, real-world evidence, and innovative reimbursement models in supporting the adoption...
In this interview, guest experts...
02/28/2025
First Report Managed Care
News
Study Finds At-Risk Medicare Advantage Plans Lead in Quality and Efficiency
02/11/2025
A recent study published in JAMA Network Open provides evidence that at-risk Medicare Advantage (MA) payment arrangements lead to superior quality and efficiency in health care delivery compared with fee-for-service (FFS) MA models.
A recent study published in JAMA Network Open provides evidence that at-risk Medicare Advantage (MA) payment arrangements lead to superior quality and efficiency in health care delivery compared with fee-for-service (FFS) MA models.
A recent study published in JAMA...
02/11/2025
First Report Managed Care
News
90% ROI on Mental Health Benefits
02/07/2025
A recent study published in JAMA Network Open highlights the financial benefits of employer-sponsored behavioral health programs, demonstrating that these programs can result in significant net medical costs savings.
A recent study published in JAMA Network Open highlights the financial benefits of employer-sponsored behavioral health programs, demonstrating that these programs can result in significant net medical costs savings.
A recent study published in JAMA...
02/07/2025
First Report Managed Care
News
Biosimilar Competition Reduces Adalimumab Spending but Faces Challenges in Uptake
01/20/2025
In the first year of biosimilar competition for adalimumab, spending on the drug decreased by nearly 50%, yet biosimilars accounted for less than 2% of prescriptions in the US.
In the first year of biosimilar competition for adalimumab, spending on the drug decreased by nearly 50%, yet biosimilars accounted for less than 2% of prescriptions in the US.
In the first year of biosimilar...
01/20/2025
First Report Managed Care
Headshots
Commentary
How to Maximize the Value of GLP-1 Drugs While Improving Health Equity
01/14/2025
GLP-1 drugs present significant financial and health equity challenges, offering transformative benefits for obesity and cardiometabolic disorders while requiring data-driven strategies for cost-effective and equitable access.
GLP-1 drugs present significant financial and health equity challenges, offering transformative benefits for obesity and cardiometabolic disorders while requiring data-driven strategies for cost-effective and equitable access.
GLP-1 drugs present significant...
01/14/2025
First Report Managed Care
News
Study Highlights the Substantial Economic and Health Care Burden of Vitiligo
01/13/2025
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US...
01/13/2025
First Report Managed Care
News
Biosimilars Expand Access and Cut Costs in HER2-Positive Cancer Treatment
01/10/2025
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of...
01/10/2025
First Report Managed Care
News
Evaluating Long-Term Cost Benefits of Etranacogene Dezaparvovec in Hemophilia B Management
12/19/2024
A study published in Journal of Managed Care and Specialty Pharmacy evaluated the budgetary implications of introducing etranacogene dezaparvovec, a novel gene therapy for hemophilia B, into a US commercial health plan.
A study published in Journal of Managed Care and Specialty Pharmacy evaluated the budgetary implications of introducing etranacogene dezaparvovec, a novel gene therapy for hemophilia B, into a US commercial health plan.
A study published in Journal of...
12/19/2024
First Report Managed Care
News
Financial Hardships Associated With Long COVID Across Income and Education Levels
12/19/2024
A study published in Health Services Research analyzing data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) has revealed a significant association between long COVID and financial hardships.
A study published in Health Services Research analyzing data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) has revealed a significant association between long COVID and financial hardships.
A study published in Health...
12/19/2024
First Report Managed Care
News
Oncology Biosimilars Offer Cost-Efficient Solutions for Sustainable Health Care
12/19/2024
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have...
12/19/2024
First Report Managed Care
Expert Perspectives
Commentary Videos

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use